CHINYERE OBAKHUME: Open Payments
NPI 1134683816 · FONTANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,246 in 104 payments from 15 companies in 2025. Trend: 2023 $870 · 2024 $1,566 · 2025 $2,246
Food & beverage: $2,246
| Company | Payments | Amount |
|---|---|---|
| Corium, LLC | 13 | $322 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $278 |
| Otsuka America Pharmaceutical, Inc. | 16 | $268 |
| Teva Pharmaceuticals USA, Inc. | 14 | $249 |
| Alkermes, Inc. | 8 | $217 |
| Vanda Pharmaceuticals Inc. | 11 | $211 |
| ABBVIE INC. | 14 | $205 |
| Janssen Pharmaceuticals, Inc | 5 | $204 |
| Neurocrine BioSciences, Inc. | 4 | $100 |
| Axsome Therapeutics, Inc. | 4 | $78 |
Products named: Azstarys, CAPLYTA, VRAYLAR, REXULTI, INVEGA SUSTENNA, AUSTEDO XR, LYBALVI, HETLIOZ.
Industry payments across CA — which companies pay providers there.
